文献速递复苏、休克与脓毒症心脑血管急症

复苏期间抗心律失常药物给药对再次心脏骤停发生率及复苏期间心电图特征的影响:ROC ALPS 试验

Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial.
PubMed 文献 · Resuscitation · 2018-05-24
一句话结论在院外心脏骤停复苏中,与生理盐水安慰剂相比,胺碘酮或利多卡因给药并未降低首次自主循环恢复后的再次心脏骤停发生率,而再次心脏骤停与较差的生存和神经功能结局相关。

该研究为 ROC ALPS 试验的二次分析,纳入首次院前自主循环恢复前接受随机研究药物的 1144 例(40.4%)院外心脏骤停病例。总体再次心脏骤停发生率为 44.0%,安慰剂组 42.9%、利多卡因组 45.7%、胺碘酮组 43.0%。多变量逻辑回归显示,ALPS 治疗分组与再次心脏骤停无关联,但再次心脏骤停与较差的生存和神经功能结局相关。首次可用的室颤心电图 AMSA 和中位斜率与再次心脏骤停病例状态相关,中位斜率和中心频率与 ALPS 治疗分组相关。

要点

  • 在首次院前自主循环恢复前接受研究药物的 1144 例(40.4%)院外心脏骤停病例中,总体再次心脏骤停发生率为 44.0%。
  • 再次心脏骤停发生率:安慰剂组 42.9%、利多卡因组 45.7%、胺碘酮组 43.0%,多变量逻辑回归显示 ALPS 治疗分组与再次心脏骤停无关联。
  • 再次心脏骤停与较差的生存和神经功能结局相关。
  • 首次可用的室颤心电图 AMSA 和中位斜率与再次心脏骤停病例状态相关,中位斜率和中心频率与 ALPS 治疗分组相关。

适用人群与场景

  • ROC ALPS 试验中首次院前自主循环恢复前接受随机研究药物的院外心脏骤停病例,共 1144 例(40.4%)。

诊断标准与关键阈值

  • 再次心脏骤停定义为自主循环恢复后脉搏丧失,从急救医疗服务记录中确认。

红旗征与不能漏的情况

  • 再次心脏骤停与较差的生存和神经功能结局相关。

研究设计与关键结果

  • 研究类型:ROC ALPS 试验的二次分析;样本量 1144 例(40.4%)首次院前自主循环恢复前接受研究药物的病例。
  • 总体再次心脏骤停发生率为 44.0%;安慰剂组 42.9%、利多卡因组 45.7%、胺碘酮组 43.0%。
  • 多变量逻辑回归模型中,ALPS 治疗分组与再次心脏骤停无关联,但再次心脏骤停与较差的生存和神经功能结局相关。
  • 首次可用的室颤心电图 AMSA 和中位斜率与再次心脏骤停病例状态相关,中位斜率和中心频率与 ALPS 治疗分组相关。

证据类型、等级与局限

  • 证据类型:ROC ALPS 试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论:再次心脏骤停发生率在抗心律失常药物组与安慰剂组之间无差异;心电图波形特征与治疗分组和再次心脏骤停相关;再次心脏骤停与生存和神经功能结局呈负相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Intra-resuscitation antiarrhythmic drugs may improve resuscitation outcomes, in part by avoiding rearrest, a condition associated with poor out-of-hospital cardiac arrest (OHCA) outcomes. However, antiarrhythmics may also alter defibrillation threshold. The objective of this study was to investigate the relationship between rearrest and intra-resuscitation antiarrhythmic drugs in the context of the Resuscitation Outcomes Consortium (ROC) amiodarone, lidocaine, and placebo (ALPS) trial.

HYPOTHESIS: Rearrest rates would be lower in cases treated with amiodarone or lidocaine, versus saline placebo, prior to first return of spontaneous circulation (ROSC). We also hypothesized antiarrhythmic effects would be quantifiable through analysis of the prehospital electrocardiogram.

METHODS: We conducted a secondary analysis of the ROC ALPS trial. Cases that first achieved prehospital ROSC after randomized administration of study drug were included in the analysis. Rearrest, defined as loss of pulses following ROSC, was ascertained from emergency medical services records. Rearrest rate was calculated overall, as well as by ALPS treatment group. Multivariable logistic regression models were constructed to assess the association between treatment group and rearrest, as well as rearrest and both survival to hospital discharge and survival with neurologic function. Amplitude spectrum area, median slope, and centroid frequency of the ventricular fibrillation (VF) ECG were calculated and compared across treatment groups.

RESULTS: A total of 1144 (40.4%) cases with study drug prior to first ROSC were included. Rearrest rate was 44.0% overall; 42.9% for placebo, 45.7% for lidocaine, and 43.0% for amiodarone. In multivariable logistic regression models, ALPS treatment group was not associated with rearrest, though rearrest was associated with poor survival and neurologic outcomes. AMSA and median slope measures of the first available VF were associated with rearrest case status, while median slope and centroid frequency were associated with ALPS treatment group.

CONCLUSION: Rearrest rates did not differ between antiarrhythmic and placebo treatment groups. ECG waveform characteristics were correlated with treatment group and rearrest. Rearrest was inversely associated with survival and neurologic outcomes.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Salcido DD, Schmicker RH, Kime N, et al. Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial. Resuscitation. 2018. PMID: 29803703. doi:10.1016/j.resuscitation.2018.05.028

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。